



# DETERMINATION OF RELATIVE POTENCY AS THE RATIO OF EFFECTIVE CONCENTRATION ESTIMATED FROM SIGMOIDAL-RESPONSE CURVES AND RESPECTIVE MEASUREMENT UNCERTAINTY



Felipe Rebello Lourenço<sup>1\*</sup>

<sup>1\*</sup>Department of Pharmacy/School of Pharmaceutical Sciences, University of São Paulo, Brazil, [feliperl@usp.br](mailto:feliperl@usp.br)

## INTRODUCTION

Bioassays are *in vivo*, *ex vivo* or *in vitro* assays often used for the determination of the activity or relative potency ( $\rho$ ) of drug products, which may be applied during process development, product development or product release testing. Bioassays are typically performed using a parallel-assay or a sigmoidal curve assay. Assuming that the standard ( $S$ ) and test ( $T$ ) samples are biologically similar, the test sample can be expected to behave like a dilution of the standard ( $d_T = \rho \times d_S$ ). When sigmoidal curve assays are adopted, the relative potency is calculated as the ratio of effective concentration of test sample and standard ( $\rho = EC50\%_T / EC50\%_S$ ).<sup>1</sup> The standard uncertainties of the effective concentrations of test ( $u_{EC50\%_T}$ ) and standard ( $u_{EC50\%_S}$ ) is used to calculate the combined uncertainty of the relative potency ( $u_\rho$ ). However,  $EC50\%_T$  and  $EC50\%_S$  may be correlated due to shared relevant experimental conditions, which may affect the measurement uncertainty of the relative potency ( $u_\rho$ ).<sup>2</sup> The aim of this work was to propose a methodology for the measurement uncertainty evaluation of the relative potency determined using a smartphone-based colorimetric assay and sigmoidal-response curves.

## EXPERIMENTAL METHODS


Aliquots of standard and test samples in a range from 100 to 0.2  $\mu\text{g}\cdot\text{mL}^{-1}$  was transferred to a 96-well microtiter plate, followed by the addition of tryptic soy broth (TSB) previously inoculated with  $10^5$ - $10^6$  CFU $\cdot\text{mL}^{-1}$  of *Staphylococcus aureus* (ATCC 6538 –  $10^5$ - $10^6$  CFU $\cdot\text{mL}^{-1}$ ) and resazurin solution. Microtiter plate was incubated at  $37 \pm 1^\circ\text{C}$  for 90 minutes. After incubation, the microbial growth inhibition was measured using a smartphone camera device and a colour analyser app (RGB - Red-Green-Blue).

## RESULTS AND DISCUSSION

A 4-parameter logistic regression model was used to explain the microbial inhibition growth ( $Y\%$ ) as function of the logarithm of the antibiotic ( $\ln(d)$ ), as presented in the equation below:

$$Y\% = A + \frac{(D - A)}{1 + e^{B \times (\ln(C) - \ln(d))}}$$

The upper and lower asymptotes ( $A$  and  $D$ , respectively), the slope ( $B$ ) and the inflection point ( $C$ ) are expected to be the same for both standard ( $S$ ) and test ( $T$ ) sigmoidal curves, since the standard and test samples are assumed to be biologically similar, as can be seen of **Figure 1**.



**Figure 1.** Sigmoidal curves for standard ( $S$ ) and test ( $T$ ) samples.

$EC50\%_T$  and  $EC50\%_S$  values were found to be 1.18 and 1.16  $\mu\cdot\text{mL}^{-1}$  and the respective uncertainty factors ( $U_F$ ) were 1.065 and 1.061, respectively. In addition,  $EC50\%_T$  and  $EC50\%_S$  quantity values were significantly correlated ( $r = 0.83$ ), due to shared experimental conditions. Kragten spreadsheet method<sup>3</sup> were used to estimate the measurement uncertainty associated with the relative potency calculate as the ratio of effective concentration of test sample and standard. Considering the correlation between  $EC50\%_T$  and  $EC50\%_S$  quantity values, the relative potency was found to be 98.5% \*,/ 1.036. While the relative potency was found to be 98.5% \*,/ 1.091, when the correlation between  $EC50\%_T$  and  $EC50\%_S$  quantity values were not considered. The target uncertainty factor ( $U_F^{\text{target}}$ ) was found to be 1.052, considering the specification range from 90 to 135% for relative potency.

## CONCLUSION

The correlation between  $EC50\%_T$  and  $EC50\%_S$  quantity values reduced significantly the uncertainty factor for relative potency, which is smaller than the target uncertainty factor.

## REFERENCES

- Saviano A.M., Bettencourt da Silva R.J.N., Lourenço F.R., *Regul. Toxicol. Pharmacol.* **2019**, *102*, 117-124.
- Lourenço F.R.; Bettencourt da Silva R.J.N., *Talanta*. **2019**, *196*, 174-181.

## ACKNOWLEDGMENTS

This work was supported by FAPESP (Brazil).

## KEYWORDS

Bioassays, relative potency, measurement uncertainty, multiplicative uncertainty factor, correlation.